کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4752840 1416373 2017 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Understanding the process-induced formation of minor conformational variants of Erwinia chrysanthemi l-asparaginase
موضوعات مرتبط
مهندسی و علوم پایه مهندسی شیمی بیو مهندسی (مهندسی زیستی)
پیش نمایش صفحه اول مقاله
Understanding the process-induced formation of minor conformational variants of Erwinia chrysanthemi l-asparaginase
چکیده انگلیسی


- Non-PTM conformational variants of l-asparaginase are formed during manufacture.
- These variants retain activity, but are detected as separate forms by ion-exchange.
- The formation of variants was found to relate to pH and hold time during processing.
- Tendency towards variant formation may be predicted by DSC melt temperature.

During Erwinia chrysanthemi l-asparaginase (ErA) manufacture, minor conformational variants are formed that elute in the acidic region of the analytical ion-exchange HPLC chromatogram. These variants retain enzymatic activity and form part of the biopharmaceutical product, but must be kept within acceptable limits through controlled operation of the manufacturing process. The high isoelectric point of the ErA native tetramer (8.6) leads to certain process steps being operated in the alkaline pH region. Previously, the formation of these species during processing was not fully understood. In this work, in-process samples were analysed, and alkaline pH (8-9) and hold time were found to be the governing parameters. Formation of ErA acidic species was found to be accelerated at higher pH values and longer hold times, suggesting potential control strategies for the manufacturing process. However, the kinetics of ErA conformational variant formation were found to be slow (0.15-0.25 percent per day at pH 8.5). Changes in the ErA melt temperature (Tm) with pH as determined by both differential scanning calorimetry and differential scanning fluorimetry were found to be predictive of the tendency to form the IEX-HPLC acidic species during processing. Biopharmaceutical process developers should be aware of such changes to proteins and build relevant control strategies into process validation plans.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Enzyme and Microbial Technology - Volume 98, March 2017, Pages 26-33
نویسندگان
, , , , , ,